Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018006287/f8-k.htm
August 2022
August 2022
June 2022
May 2022
April 2022
February 2022
January 2022
December 2021
November 2021
August 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018006287/f8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACRSEvents:
CIK: 1557746
Form Type: 8-K Corporate News
Accession Number: 0001558370-18-006287
Submitted to the SEC: Fri Aug 03 2018 7:15:26 AM EST
Accepted by the SEC: Fri Aug 03 2018
Period: Friday, August 3, 2018
Industry: Pharmaceutical Preparations